GlassScriptPhysician profile
Jennifer Burger
NPI 1134629256
$6,500.71
in general payments reported to CMS, 2019-2025
25 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,683 · 2022: $1,240 · 2023: $411 · 2024: $1,578 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,529 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.88 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,342.76 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $569.73 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.24 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $478.34 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $463.74 | 2021-2025 | Rexulti |
| Alkermes, INC. | $418.58 | 2022-2025 | Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $367.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $280.39 | 2021-2025 | Spravato |
| Almatica Pharma LLC | $205.08 | 2022-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $174.81 | 2021-2022 | |
| Bausch Health US, LLC | $140.89 | 2021-2022 | |
| Lundbeck LLC | $140.31 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $90.84 | 2021-2025 | Uzedy |
| Indivior INC. | $66.02 | 2025 | Sublocade |
| Braeburn INC. | $48.30 | 2025 | Brixadi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $41.78 | 2024-2025 | Quviviq, Quviviq |
| Corium, LLC | $40.22 | 2023-2025 | Azstarys |
| Adlon Therapeutics L.P. | $27.03 | 2021 | |
| Allergan, INC. | $21.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $20.18 | 2025 | Jornay Pm |
| Tris Pharma INC | $19.70 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $17.86 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $13.61 | 2022 | |
| Eisai INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Burger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.